



# CHONG KUN DANG

www.ckdpharm.com/en/home

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines. In 1968, CKD received US FDA approval for Chloramphenicol. Remarkably, CKD is one of the first Korean pharmaceutical companies to establish Research Center in early 1970's to accelerate the development of novel technologies and therapeutics. As a result, CKD has successfully launched two novel therapeutics, Camtobell for anti-cancer and Duvie for type 2 diabetes, and world's first NESP biosimilar, Nesbell.

## Main Products



Category	Brand Name	Ingredients	Note
Oncology	Camtobell Inj	Belotecan	New Drugs
Type 2 diabetes	Duvie Tab	Lobeglitazone	New Drugs
Antihypertensive drugs	Dilatrend Tab	Carvedilol	
Immunology	Tarcobell Cap	Tarcrolimus	
Antihyperlipidemic agent	Lipilou Tab	Atrovastain	
Nootropic Agents	CKD Gliatilin Soft Cap	Choline Alfoscerate	

CEO  
YOUNG JOO KIM

Location  
8 Chungjeong-ro, Seodaemun-gu, Seoul, Korea

Specialty  
1. Anticancer New Drugs  
2. Antidiabetic New Drugs  
3. Autoimmune Diseases

Tel / Fax / E-mail  
T. 82-2-2194-0300  
F. 82-2-2194-0369  
E. youngjookim@ckdpharm.com

## R&D Pipeline

### New Chemical Drugs/Biologics

#### CV & METABOLIC DISEASE

- Diabetes (PPAR-γ agonist)
- Dyslipidemia (CETP inhibitor)

#### ONCOLOGY

- Ovarian Cancer, SCLC (Camptothecin analogue)
- Liver Cancer (A3 adenosine receptor agonist)
- Colorectal Cancer (VDA)
- Multiple Myeloma (Pan-HDAC inhibitor)
- NSCLC, Colorectal Cancer (Bi-specific antibody)

#### IMMUNOLOGY

- SLE, Dermatomyositis (anti-INFα)
- Autoimmune Disease (HDAC6 inhibitor)

#### CNS

- Neurodegenerative Disease (HDAC6 inhibitor)

#### OTHERS

- Anemia (Darbepoetin-α)
- Ophthalmology (Ranibizumab)
- Pain, Uremic Pruritus (Opioid κ receptor agonist)
- HSDD (Hypoactive sexual desire disorder)
- Rare Disease (HDAC6 inhibitor)



∞ Biologics / \* In-licensed product